cMyC has been measured in a variety of patient groups and directly compared to cardiac troponin T (cTnT) and cardiac troponin I (cTnI) measured in the same blood samples using high-sensitivity assays.
Direct comparisons of cMyC with cTnI/T have established the following:
- cMyC is more abundant than cTnT/I and consequently it is possible to measure smaller volumes of myocardium undergoing injury, based on spiking human heart into human blood.
- After myocardial injury cMyC can be detected in the blood earlier, and its concentration rises more rapidly, than cTnT/I or novel RNA biomarkers.
- Based on blood samples taken at presentation in patients with a suspected acute coronary syndrome, the diagnostic accuracy for acute myocardial infarction of cMyC, cTnI, and cTnT are similar, but cMyC is more efficient at rapid rule out.
- Despite cMyC having a sarcomeric location and kinetic profile that differs from cTnT/I, its concentration is similarly increased by chronic myocardial injury and acute (non-ischaemic) myocardial injury.